MUMBAI GlaxoSmithKline Plc (GSK.L) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS), David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.
GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees.
The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.
The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said. (Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)
India's fiscal deficit reaches 74 percent of full-year target in July
NEW DELHI India's fiscal deficit during April-July was 3.93 trillion rupees ($58.69 billion), or 73.7 percent of the budgeted target for the fiscal year ending in March 2017, government data showed on Wednesday.
Expert views: India's economic growth slows down
MUMBAI India's economy grew at a slower than-expected pace of 7.1 percent in the three months through June from 7.9 percent in the previous quarter, government data showed on Wednesday.
Wall St opens lower as oil prices drop
U.S. stocks opened slightly lower on Wednesday as oil prices dropped more than 1 percent on the back of a stronger dollar.